ETF Holdings Breakdown of KYMR

News associated with KYMR

Wells Fargo & Company Lowers Kymera Therapeutics (NASDAQ:KYMR) Price Target to $53.00

Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $53.00 in a report released on Thursday morning,Benzinga reports. They currently have an overweight rating on the stock. Other equities analysts have also issued research reports about the company. Wall Street Zen upgraded Kymera Therapeutics from […] - 2025-06-27 07:46:43

Kymera Therapeutics (NASDAQ:KYMR) Upgraded by Bank of America to “Buy” Rating

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) was upgraded by research analysts at Bank of America from a “neutral” rating to a “buy” rating in a research note issued to investors on Monday, Marketbeat.com reports. The firm currently has a $51.00 price target on the stock. Bank of America‘s price objective points to a potential […] - 2025-06-04 05:50:56

Kymera Therapeutics (NASDAQ:KYMR) Sees Large Volume Increase on Analyst Upgrade

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) shares saw strong trading volume on Tuesday after JPMorgan Chase & Co. raised their price target on the stock from $57.00 to $64.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. 961,245 shares changed hands during mid-day trading, an increase of 62% from […] - 2025-06-04 05:01:25

Universal Beteiligungs und Servicegesellschaft mbH Invests $4.61 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 114,587 shares of the company’s stock, valued at approximately $4,610,000. Universal Beteiligungs und […] - 2025-06-02 08:36:54

Bank of America Corp DE Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Bank of America Corp DE cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 43.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,260 shares of the company’s stock after selling 48,772 shares during the quarter. Bank of America […] - 2025-06-02 07:38:48

BNP Paribas Financial Markets Makes New $396,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

BNP Paribas Financial Markets acquired a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,838 shares of the company’s stock, valued at approximately $396,000. Several other hedge […] - 2025-05-26 07:24:47

D. E. Shaw & Co. Inc. Lowers Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

D. E. Shaw & Co. Inc. cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 56.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 82,578 shares of the company’s stock after selling 105,619 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Kymera Therapeutics were worth […] - 2025-05-19 08:12:56

Northern Trust Corp Grows Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Northern Trust Corp raised its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 14.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 437,833 shares of the company’s stock after acquiring an additional 53,658 shares during the quarter. Northern Trust Corp’s holdings in Kymera Therapeutics were worth $17,614,000 as of […] - 2025-05-15 08:38:47

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Comerica Bank

Comerica Bank cut its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 45.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 20,631 shares of the company’s stock after selling 17,442 shares during the quarter. Comerica Bank’s holdings in Kymera Therapeutics were worth $830,000 at the end of the most recent reporting […] - 2025-05-14 08:19:05

Guggenheim Reaffirms “Buy” Rating for Kymera Therapeutics (NASDAQ:KYMR)

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research report issued on Monday,Benzinga reports. They presently have a $52.00 price target on the stock. Guggenheim’s price objective points to a potential upside of 66.99% from the company’s current price. A number of […] - 2025-05-14 06:10:53

Tower Research Capital LLC TRC Increases Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Tower Research Capital LLC TRC increased its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 95.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,812 shares of the company’s stock after purchasing an additional 2,350 shares during the […] - 2025-05-06 08:16:52

Marshall Wace LLP Sells 110,846 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Marshall Wace LLP decreased its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 94.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,835 shares of the company’s stock after selling 110,846 shares during the period. Marshall Wace LLP’s holdings in […] - 2025-05-05 08:04:51

Wells Fargo & Company MN Has $883,000 Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Wells Fargo & Company MN grew its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 51.8% during the fourth quarter, Holdings Channel reports. The firm owned 21,939 shares of the company’s stock after acquiring an additional 7,487 shares during the quarter. Wells Fargo & Company MN’s holdings in Kymera Therapeutics were worth $883,000 […] - 2025-05-01 07:35:02

Franklin Resources Inc. Acquires 8,927 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Franklin Resources Inc. raised its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 30.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 38,367 shares of the company’s stock after acquiring an additional 8,927 shares during the period. Franklin Resources Inc. owned approximately 0.06% […] - 2025-04-15 08:32:48

Alliancebernstein L.P. Cuts Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Alliancebernstein L.P. lessened its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 29.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 88,246 shares of the company’s stock after selling 36,368 shares during the quarter. Alliancebernstein L.P.’s holdings in Kymera Therapeutics were worth $3,550,000 as of its most recent filing with the […] - 2025-04-15 07:50:48

Norges Bank Invests $3.67 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Norges Bank acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 91,231 shares of the company’s stock, valued at approximately $3,670,000. Several other large investors have also bought and […] - 2025-04-11 08:12:59

Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $56.36

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has earned an average rating of “Moderate Buy” from the fifteen research firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-04-11 06:08:47

Vanguard Group Inc. Acquires 133,546 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Vanguard Group Inc. grew its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 2.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,887,312 shares of the company’s stock after purchasing an additional 133,546 shares during the quarter. Vanguard Group Inc. owned about 0.08% of Kymera Therapeutics worth $196,617,000 […] - 2025-04-07 07:34:48

Teacher Retirement System of Texas Increases Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Teacher Retirement System of Texas raised its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 35.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 11,490 shares of the company’s stock after purchasing an additional 3,026 shares during the period. Teacher Retirement System of Texas’ holdings in Kymera Therapeutics were worth […] - 2025-04-01 07:40:45

Charles Schwab Investment Management Inc. Boosts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Charles Schwab Investment Management Inc. lifted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 5.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 387,187 shares of the company’s stock after purchasing an additional 20,346 shares during the quarter. […] - 2025-03-21 07:10:59

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen research firms that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has given a strong buy […] - 2025-03-14 06:41:01

New York State Common Retirement Fund Has $585,000 Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

New York State Common Retirement Fund cut its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 7.0% during the fourth quarter, Holdings Channel reports. The fund owned 14,549 shares of the company’s stock after selling 1,100 shares during the period. New York State Common Retirement Fund’s holdings in Kymera Therapeutics were […] - 2025-03-05 08:41:05

Critical Survey: Kymera Therapeutics (NASDAQ:KYMR) and Cardiff Oncology (NASDAQ:CRDF)

Cardiff Oncology (NASDAQ:CRDF – Get Free Report) and Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability. Profitability This table compares Cardiff Oncology and […] - 2025-03-05 06:40:46

Kymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week Low on Disappointing Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report)’s share price reached a new 52-week low on Friday after the company announced weaker than expected quarterly earnings. The company traded as low as $29.22 and last traded at $29.98, with a volume of 1722609 shares. The stock had previously closed at $35.36. The company reported ($0.88) […] - 2025-02-28 06:46:47

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $55.06 Consensus PT from Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has earned an average rating of “Moderate Buy” from the seventeen ratings firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to […] - 2025-02-20 06:30:50

KBC Group NV Boosts Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

KBC Group NV boosted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 53.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,151 shares of the company’s stock after purchasing an additional 752 shares during the quarter. KBC Group NV’s holdings in Kymera Therapeutics were worth $87,000 at the end of the […] - 2025-02-10 18:33:11

Kymera Therapeutics (NASDAQ:KYMR) & Gene Biotherapeutics (OTCMKTS:CRXM) Financial Review

Gene Biotherapeutics (OTCMKTS:CRXM – Get Free Report) and Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations. Earnings & Valuation This table compares Gene Biotherapeutics […] - 2025-02-10 18:12:50

KYMR institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	24,883	USD 1,137,402 -1.7%
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	20,372	USD 931,204
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	32,495	USD 1,485,346
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	32,495	USD 1,485,346
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,556	USD 71,125
Total =		111,801	USD 5,110,423

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer